{
  "nctrialId": "HC-2123",
  "title": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of OST-957 (cathepsin K inhibitor) in Patients With Psoriasis",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of OST-957 (cathepsin K inhibitor) in Patients With Psoriasis",
  "sponsor": "University Health Network",
  "indication": "Psoriasis",
  "phase": "Phase 2",
  "fileName": "HC-2123.json",
  "fileSize": 493840,
  "date": "2024-08-31",
  "completionDate": "2026-03-11",
  "drugName": "OST-957 (cathepsin K inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Completed",
  "description": "This is a randomized double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of OST-957 (cathepsin K inhibitor) in patients with Psoriasis. The study will enroll approximately 235 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 19-55 years\n- Confirmed diagnosis of Psoriasis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}